Data appendix
The indicator set with its sources, the source registers, the licences of every kind of material and the formats of the edition.
فہرست مضامین
- ·Edition home
- ·Executive summary
- 1Genomics is data infrastructure and a therapeutic frontier
- 2Key findings
- 3Systems and sectors at baseline
- 4Risks and capability
- 5Individualised editing outpaces delivery systems
- 6Readings from the other desks
- 7The 2027 agenda
- 8Systems in depth
- Aطریقۂ کار
- BData appendix
- CReferences and record
- ·Complete edition, for print
B.1The indicator set
| Indicator | قدر | Unit | سال | ریاست | ماخذ |
|---|---|---|---|---|---|
| Patients treated with exa-cel, sickle cell study | 44 | patients | 2024 | رپورٹ شدہ | 2 |
| Evaluable patients, sickle cell study | 30 | patients | 2024 | رپورٹ شدہ | 2 |
| Free of severe crises for 12 months or more | 29 | patients | 2024 | رپورٹ شدہ | 2 |
| Median follow-up, sickle cell study | 19.3 | months | 2024 | رپورٹ شدہ | 2 |
| Patients treated with exa-cel, thalassaemia study | 52 | patients | 2024 | رپورٹ شدہ | 3 |
| Transfusion independent, evaluable patients | 32 of 35 | patients | 2024 | رپورٹ شدہ | 3 |
| Base pairs in T2T-CHM13 | 3.055 | billion | 2022 | رپورٹ شدہ | 11 |
| New sequence in T2T-CHM13 | ≈200 | million bp | 2022 | رپورٹ شدہ | 11 |
| Phased assemblies in draft pangenome | 47 | assemblies | 2023 | رپورٹ شدہ | 12 |
| Added sequence in draft pangenome | 119 | million bp | 2023 | رپورٹ شدہ | 12 |
| UK Biobank whole genomes | 490,640 | participants | 2025 | رپورٹ شدہ | 16 |
| All of Us genomes released | 245,388 | genomes | 2024 | رپورٹ شدہ | 17 |
| Casgevy revenue, first quarter 2026 | 42.9 | USD million | 2026 | رپورٹ شدہ | 6 |
| Casgevy revenue, first quarter 2025 | 14.2 | USD million | 2025 | رپورٹ شدہ | 6 |
| Genetic counsellor jobs | ≈4,200 | jobs | 2025 | رپورٹ شدہ | 33 |
| Newborn genomes planned in Generation Study | 100,000 | babies | 2026 | رپورٹ شدہ | 34 |
B.2Global source register
The governed source set behind this edition. Each source keeps its authority, coverage, cadence and role; categories describe origin, not truth.
Domains bound by the register
- HLT
- DAT
- FIN
- TRD
- ENE
- INF
- GOV
- FOO
- BIO
- AIC
| ماخذ | Category | احاطہ | Period | Cadence | کردار |
|---|---|---|---|---|---|
| Frangoul et al., NEJM2 | peer-reviewed journal | sickle cell | 2024 | one-off | therapy |
| Locatelli et al., NEJM3 | peer-reviewed journal | thalassaemia | 2024 | one-off | therapy |
| FDA approval notice1 | national regulator | US | 2023 | one-off | approval |
| Nurk et al., Science11 | peer-reviewed journal | method | 2022 | one-off | reference genome |
| UK Biobank and All of Us papers1617 | peer-reviewed journal | UK and US | 2024 to 2025 | periodic | cohorts |
| Grealey et al.21 | peer-reviewed journal | method | 2022 | one-off | compute footprint |
| Vertex first quarter report6 | company | global | 2026 | quarterly | revenue |
| Illumina and Ultima pages1415 | vendor | global | 2026 | continuous | hardware claims |
| BIOSECURE and Illumina China summaries3031 | law firm and trade press | US and China | 2025 | per event | trade |
| BLS Occupational Outlook33 | national statistics office | US | 2025 | annual | workforce |
B.3Regional reading, genomics across ten clusters
Regional plates follow with the regional editions. This page gives the regional reading of genomics infrastructure and exposure in table form and ranks no region.
| خطہ | Principal hazards | Systems most exposed | Baseline evidence |
|---|---|---|---|
| شمالی امریکہ | approvals; large cohorts; trade and procurement law | therapies, data, trade | FDA1; All of Us17; BIOSECURE30 |
| جنوبی امریکہ | early programmes; access gaps | access | regional evidence (not bound) |
| یورپ | UK Biobank and newborn sequencing; plant-editing rules | data, rules | UK Biobank16; Generation Study34; Act29 |
| Eurasia | research programmes; export controls | research, supply | regional evidence (not bound) |
| مشرق وسطیٰ اور شمالی افریقہ | treatment access in several countries | access | Vertex report6 |
| افریقہ | cost-effectiveness for sickle cell therapy in Uganda | access, cost | Uganda analysis8 |
| جنوبی ایشیا | national genome programmes | data, skills | regional evidence (not bound) |
| مشرقی ایشیا | sequencer trade controls; domestic platforms | supply, trade | MedTech Dive31 |
| ASEAN | programmes and partnerships | data, supply | regional evidence (not bound) |
| Oceania-Pacific | research programmes; skills | research, workforce | regional evidence (not bound) |
B.4Cluster card: ex vivo editing therapy chain
- cell therapy
- cold chain
- treatment centres
- single point
- Systems in view
- cell collection, editing, manufacture, conditioning, infusion
- Defining events
- approval on 8 December 2023 and a pediatric submission in 202616
- Couplings
- HLT → FIN payment; INF → HLT manufacturing capacity
- Capability evidence
- authorised treatment centres reported by the company6
- Gaps
- patients treated; prices; cold-chain energy
- Agenda items
- Q-01 · Q-02
A 2026 analysis states that gene therapy access is limited by cost and manufacturing capacity in the United States and globally [7].
ACCESS
Capacity and cost
Vertex reported USD 42.9 million of Casgevy revenue in the first quarter of 2026 and has submitted for children 5 to under 12 [6].
MARKET
Revenue from a small base
A cost-effectiveness analysis compares gene therapy with haploidentical transplantation and standard care [7].
RESPONSE
Alternatives
B.5How countries appear in the genomics edition
Countries enter the genomics edition through the readiness chapters of their own national editions, on one card grammar. They are read against peer distributions and thresholds, never ranked.
| Card field | What it shows | ماخذ |
|---|---|---|
| WEFH+B state | each core system against peer distribution bands | national edition |
| Couplings | the national dependency matrix | national edition |
| Risk objects | the national risk portfolio | national edition |
| Capability rungs | the national capability ladder | national edition |
| Evidence age | oldest and newest source dates | national source register |
Editions in the 2026 Baseline programme
countries and unions
clusters
flagship and sector
technology reports
How to read a country card
- Each system is shown against the distribution of its peers, with thresholds where they exist
- Couplings and risk objects come from the country’s own national edition
- Capability rungs record evidence, not a judgement of institutions
- Evidence age is printed, so older national data are visible as such
| Wave | Countries and unions | ریاست |
|---|---|---|
| W0 | کینیڈا | ISSUED |
| W1 | United States, United Kingdom, France, Germany, Italy, Japan, European Union, Switzerland | PLANNED |
| W2 | Mexico, Brazil, Argentina, Türkiye, Russian Federation, Saudi Arabia, United Arab Emirates, South Africa, Senegal, Kenya, African Union, India, China, Republic of Korea, Indonesia, Singapore, Australia | PLANNED |
B.6لائسنس
| Material | لائسنس |
|---|---|
| Text | CC BY 4.0 |
| ڈیٹا | on the licence of each source; Nexus tables CC BY 4.0 |
| Figures | Nexus figures CC BY 4.0; third-party as credited |
| نقشے | boundary source and licence printed on each plate |
| Metadata | CC0 1.0, as Zenodo publishes it |
| Third-party data, figures and text | The source’s own licence, credited where it is used; never relicensed |
| Nexus-authored text, tables and figures: CC BY 4.0 (SPDX CC-BY-4.0). Map plates print their boundary source and licence. | |
B.7Formats and provenance
| Format | Kind | ریاست | یہ کیا ہے | Identifier |
|---|---|---|---|---|
| Web edition | HTML | On this site | Draft in stewardship review; every value resolves to its source. | NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0 |
| Print edition | At release | A4 portrait · screen, print and archival PDF, signed with the web edition at release. | NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0 | |
| Indicator data | CSV · JSON | On this site | 16 indicators with unit, year, status and source; the machine-readable copy ships with the evidence bundle at release. | NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE data release v1 |
| Figures | SVG · PNG | On this site | 4 on the web edition: headline figure, figure 1.3, coupling instrument, capability ladder. | FIG-XTECH-GENOMICS-GLOBAL-2026-BASELINE-* |
| Slides | Not recorded | No slide deck is recorded for this edition. | ||
| Evidence brief | HTML · PDF | Not recorded | No evidence brief is recorded for this edition. | |
| Dataset with DOI | DataCite | At release | Concept and version DOI are minted at deposit; none is recorded yet. |
ماخذ کا سراغ
- Edition pack
- The edition’s content pack (JSON), from which the print and web editions are built
- Evidence cut
- DC-XTECH-GENOMICS-GLOBAL-2026-B0, closed 30 September 2026
- Reproducibility
- sourced values cited; analytical values reproducible from stated parameters
- Self-check
- 14 of 23 at evidence close; a fail on any item blocks release
- جائزہ
- five passes scheduled before release (in Annex C)
- Publisher of record
- The Global Centre for Risk and Innovation (GCRI) for the Nexus Consortium
- تصحیحات
- Registry correction pathway; upheld corrections are published as notices with a new version
Notes
Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references
- 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
- 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
- 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
- 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
- 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
- 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
- 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03.back
- 33US Bureau of Labor Statistics (ed.), Occupational Outlook Handbook: Genetic Counselors (about 4,200 jobs in 2025; median pay USD 100,040 in May 2025; 10% growth projected 2025 to 2035). BLS, Washington. Observation year 2025. Accessed 2026-11-03.back
- 34Genomics England (ed.), Generation Study: newborn genome sequencing (initiative page; 100,000 babies; more than 200 conditions; recruitment progress not stated). Genomics England, London. Observation year 2026. Accessed 2026-11-03.back
- 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
- 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03.back
- 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03.back
- 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
- 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03.back
- 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
- 29UK Parliament (ed.), Genetic Technology (Precision Breeding) Act 2023, 2023 c. 6 (contents page read; section texts not read). UK Parliament, London. Observation year 2023. Accessed 2026-11-03.back
- 8Montano-Campos, J.F. et al., Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda context, Gene Therapy 2026 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2026. Accessed 2026-11-03.back